Friday, 4 September 2026European Markets

NR21 Stock Is 9% Up So Far On Tuesday

Loading stream...

(vianews) - shares of nr21 (cac 40: nr21.pa) rose 9.58% to €91.50 at 14:07 est on tuesday, after five sequential sessions in a row of losses. cac 40 is sliding 0.05% to €7,180.76, following the last session's upward trend. this seems, up to now, a somewhat down trend exchanging session today.

nr21's last close was €83.50, 63.38% under its 52-week high of €228.00.

about nr21

nr21 société anonyme does not have significant operations. previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. the company is based in paris, france.

earnings per share

as for profitability, nr21 has a trailing twelve months eps of €-1.17.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, nr21's stock is considered to be overbought (>=80).

volatility

nr21's last week, last month's, and last quarter's current intraday variation average was a negative 6.59%, a negative 5.92%, and a positive 6.43%.

nr21's highest amplitude of average volatility was 6.59% (last week), 5.92% (last month), and 6.43% (last quarter).

more news about nr21 (nr21.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com